20 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 20 of 20 clinical reviews.
GLP-1 receptor agonists, especially semaglutide and tirzepatide, have produced meaningful MASH resolution rates in randomized trials. Here is what is established, what is still evolving, and how to think about eligibility.
A clinical deep-dive into whether metabolic-associated steatotic liver disease can fully reverse through diet alone, covering caloric targets, macronutrient strategies, coffee, GLP-1 drugs, and non-invasive fibrosis testing.
MASLD (formerly NAFLD) is now the leading driver of cirrhosis worldwide. Learn how hepatic steatosis progresses to MASH and irreversible fibrosis, what the evidence says about reversal, and which therapies are FDA-approved or in late-stage trials.
A detailed breakdown of resmetirom (Rezdiffra) costs in 2026, including list price, insurance coverage, patient assistance programs, and how to reduce out-of-pocket spending for MASLD/MASH treatment.
How cryptogenic cirrhosis is diagnosed, when burned-out MASH is plausible, and how cancer surveillance, portal hypertension, nutrition, and transplant care are managed.
Coffee may reduce liver fibrosis risk by up to 40%. This guide covers the NAFLD-to-MASLD rename, diet reversal, GLP-1 therapy, and non-invasive fibrosis testing.
An evidence-focused look at whether fructose uniquely drives metabolic dysfunction-associated steatotic liver disease, how its biochemistry differs from glucose, and what the evidence does and does not support about diet, coffee, GLP-1 therapy, and reversal.
Hepatic steatosis is fat in 5%+ of liver cells, now called MASLD. Learn causes, FIB-4 diagnosis, and the first FDA-approved MASH drug, resmetirom.
Lean MASLD affects people with a normal BMI but still causes significant liver damage. Learn who is at risk, how it differs from obesity-related MASLD, and what treatment options exist.
A guide to metabolic dysfunction-associated steatotic liver disease (MASLD): how it develops, how it is staged, and which lifestyle changes and medications can reverse it.
Over 1,000 drugs and supplements can cause liver toxicity. Learn the ALT and bilirubin thresholds doctors use to diagnose DILI and what to do next.
MASH, formerly called NASH, is the inflammatory form of metabolic fatty liver disease. Learn how it differs from simple steatosis, how it progresses to cirrhosis, and what FDA-approved and emerging therapies now exist.
MASLD replaced NAFLD in 2023. Learn what changed, how MASH (formerly NASH) is staged, which FDA-approved treatments now exist, and what your liver enzymes actually mean.
People with type 2 diabetes have a substantially higher rate of MASLD and a faster path to liver fibrosis than the general population. This article covers the mechanisms, screening tools, and evidence-based treatment options, with clear notes on what is established versus what still needs confirmation.
MASLD (metabolic dysfunction-associated steatotic liver disease) is common in people with obesity. This article explains the mechanism, risk by subgroup, and where treatment evidence is strong versus still emerging.
Postmenopausal women face a sharp rise in MASLD risk after estrogen loss. Learn how menopause, diabetes, obesity, and lean MASLD interact, plus current treatment options backed by clinical evidence.
Obeticholic acid causes pruritus in up to 70% of patients. Learn the mechanism, severity grading, management strategies, and how it compares to resmetirom and pioglitazone side effects in MASLD treatment.
Evidence-based resmetirom (Rezdiffra) dosing protocol for metabolic dysfunction-associated steatohepatitis (MASH), including weight-based dosing, titration, monitoring, and comparison with vitamin E therapy.
A guide to SGLT2 inhibitors for MASLD, MASH, and liver fibrosis, comparing empagliflozin, dapagliflozin, and canagliflozin against pioglitazone, vitamin E, obeticholic acid, and resmetirom.
A guide to vitamin E dosing in NASH (now called MASLD/MASH), covering the PIVENS trial dose, who qualifies, risks of high-dose tocopherol, and where resmetirom fits in the 2024 treatment landscape.